Abstract
A better understanding of pathways involved in survival of prostate cancer cells is the key to develop effective and target-selective therapies. Presence of serum or epidermal growth factor in the culture medium of LNCaP cells decreases apoptosis induced by the inhibition of phosphatidylinositol 3-kinase with LY294002. However, intracellular pathway(s) involved in this survival signaling are not well defined. Here, we investigated the mechanism(s) involved in serum or epidermal growth factor-mediated inhibition of LY294002-induced death in LNCaP cells. Cell death was assessed by the percentage of cells in sub-G1 phase and caspase 3 activity. Phosphorylation status of BAD, ERK1/2 and RSKs were assessed by Western blot. Specific gene expression knock down of BAD, BAX, RSK1 and RSK2 were performed using siRNA transfections. Our results demonstrate that cell death induced by LY294002 is mediated by translocation of BAD and BAX proteins from the cytosol to the mitochondria. Whereas, epidermal growth factor activates a MAPK/ERK/RSK1 module leading to inactivation of BAD via Ser75 phosphorylation, the presence of serum, on the other hand, induces a nonconducive intracellular environment for mitochondrial translocation of dephosphorylated BAD. Taken together, these results indicate that phosphorylation of BAD or inhibition of its translocation to the mitochondria are critical phosphatidylinositol 3-kinase-independent survival pathways in LNCaP cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ballif BA, Blenis J . (2001). Cell Growth Differ 12: 397–408.
Boldt S, Kolch W . (2004). Curr Pharm Des 10: 1885–1905.
Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME . (1999). Science 286: 1358–1362.
Carson JP, Kulik G, Weber MJ . (1999). Cancer Res 59: 1449–1453.
Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL et al. (2003). Int J Oncol 22: 469–480.
Chao DT, Korsmeyer SJ . (1998). Annu Rev Immunol 16: 395–419.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Cell 91: 231–241.
Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM . (2003). Cancer Res 63: 8330–8337.
Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N et al. (2004). J Biol Chem 279: 21085–21095.
Green DR, Reed JC . (1998). Science 281: 1309–1312.
Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L et al. (1980). Prog Clin Biol Res 37: 115–132.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. (1983). Cancer Res 43: 1809–1818.
Kajiwara T, Takeuchi T, Ueki T, Moriyama N, Ueki K, Kakizoe T et al. (1999). Int J Urol 6: 520–525.
Kooijman R, Coppens A, Hooghe-Peters E . (2003). Cell Signal 15: 1091–1098.
Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA . (2000). Cancer Res 60: 6052–6060.
Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ . (2002). Cancer Cell 2: 183–192.
Li X, Marani M, Mannucci R, Kinsey B, Andriani F, Nicoletti I et al. (2001). Cancer Res 61: 1699–1706.
Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA et al. (2004). J Neurosci 24: 9993–10002.
Lizcano JM, Morrice N, Cohen P . (2000). Biochem J 349: 547–557.
Lutz RJ . (2000). Biochem Soc Trans 28: 51–56.
Lyons-Darden T, Daaka Y . (2004). J Mol Endocrinol 33: 165–173.
Martinou JC, Green DR . (2001). Nat Rev Mol Cell Biol 2: 63–67.
McConkey DJ, Greene G, Pettaway CA . (1996). Cancer Res 56: 5594–5599.
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT et al. (1992). Cancer Res 52: 6940–6944.
McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM . (2002). Prostate 51: 133–140.
Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ . (2001). Endocrinology 142: 4795–4805.
Nomura T, Mimata H, Takeuchi Y, Yamamoto H, Miyamoto E, Nomura Y . (2003). Urol Res 31: 37–44.
Puthalakath H, Strasser A . (2002). Cell Death Differ 9: 505–512.
Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R . (1995). Cancer Res 55: 4438–4445.
Sato S, Fujita N, Tsuruo T . (2004). J Biol Chem 279: 33759–33767.
Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC et al. (2002). Lancet 359: 397–401.
Shi XB, Gumerlock PH, Muenzer JT, deVere White RW . (2001). Cancer Biother Radiopharm 16: 421–429.
Shimamura A, Ballif BA, Richards SA, Blenis J . (2000). Curr Biol 10: 127–135.
Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE . (2003). Prostate 56: 142–149.
Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM . (2003). J Biol Chem 278: 25872–25878.
Yarden Y . (2001). Eur J Cancer 37 (Suppl 4): S3–S8.
Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL et al. (2005). Prostate 64: 293–302.
Acknowledgements
We thank Dr C Brenner for the VDAC antibody, Dr Stanley J Korsmeyer laboratory, Dana-Farber Cancer Institute, Boston, MA, for the pcDNA3-BADwt encoding for murine BAD, Ms Wang Ya for useful technical assistance in the immunofluorescence analysis of activated BAX and Dr S Pervaiz for his help in editing the paper. This work was supported by Grant R-183-000-084-213 from The National Medical Research Council of Singapore to MVC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chao, O., Clément, MV. Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells. Oncogene 25, 4458–4469 (2006). https://doi.org/10.1038/sj.onc.1209421
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209421
Keywords
This article is cited by
-
The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance
Oncogene (2021)
-
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression
Molecular Cancer (2011)
-
Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity
Cell Death & Differentiation (2007)